Literature DB >> 22125178

Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia.

Shawn K Ahlfeld1, Simon J Conway.   

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease in infants born extremely preterm, typically before 28 weeks' gestation, characterized by a prolonged need for supplemental oxygen or positive pressure ventilation beyond 36 weeks postmenstrual age. The limited number of autopsy samples available from infants with BPD in the postsurfactant era has revealed a reduced capacity for gas exchange resulting from simplification of the distal lung structure with fewer, larger alveoli because of a failure of normal lung alveolar septation and pulmonary microvascular development. The mechanisms responsible for alveolar simplification in BPD have not been fully elucidated, but mounting evidence suggests that aberrations in the cross-talk between growth factors of the lung mesenchyme and distal airspace epithelium have a key role. Animal models that recapitulate the human condition have expanded our knowledge of the pathology of BPD and have identified candidate matrix components and growth factors in the developing lung that are disrupted by conditions that predispose infants to BPD and interfere with normal vascular and alveolar morphogenesis. This review focuses on the deviations from normal lung development that define the pathophysiology of BPD and summarizes the various candidate mesenchyme-associated proteins and growth factors that have been identified as being disrupted in animal models of BPD. Finally, future areas of research to identify novel targets affected in arrested lung development and recovery are discussed.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22125178      PMCID: PMC3256283          DOI: 10.1002/bdra.22869

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  187 in total

1.  Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury.

Authors:  Virender K Rehan; Reiko Sakurai; Julia Corral; Melissa Krebs; Basil Ibe; Kaori Ihida-Stansbury; John S Torday
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

Review 2.  Inhaled nitric oxide in preterm infants: a systematic review.

Authors:  Pamela K Donohue; Maureen M Gilmore; Elizabeth Cristofalo; Renee F Wilson; Jonathan Z Weiner; Brandyn D Lau; Karen A Robinson; Marilee C Allen
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

3.  Antecedents of chronic lung disease following three patterns of early respiratory disease in preterm infants.

Authors:  Matthew Laughon; Carl Bose; Elizabeth N Allred; T Michael O'Shea; Richard A Ehrenkranz; Linda J Van Marter; Alan Leviton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2010-08-05       Impact factor: 5.747

4.  CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia.

Authors:  Shaoyi Chen; Min Rong; Astrid Platteau; Dorothy Hehre; Heather Smith; Philip Ruiz; Jeffrey Whitsett; Eduardo Bancalari; Shu Wu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-14       Impact factor: 5.464

5.  NF-kappaB activation limits airway branching through inhibition of Sp1-mediated fibroblast growth factor-10 expression.

Authors:  John T Benjamin; Billy J Carver; Erin J Plosa; Yasutoshi Yamamoto; J Davin Miller; Jin-Hua Liu; Riet van der Meer; Timothy S Blackwell; Lawrence S Prince
Journal:  J Immunol       Date:  2010-09-22       Impact factor: 5.422

6.  Annual summary of vital statistics: 2008.

Authors:  T J Mathews; Arialdi M Miniño; Michelle J K Osterman; Donna M Strobino; Bernard Guyer
Journal:  Pediatrics       Date:  2010-12-20       Impact factor: 7.124

7.  NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants.

Authors:  F Sessions Cole; Claudia Alleyne; John D E Barks; Robert J Boyle; John L Carroll; Deborah Dokken; William H Edwards; Michael Georgieff; Katherine Gregory; Michael V Johnston; Michael Kramer; Christine Mitchell; Josef Neu; DeWayne M Pursley; Walter M Robinson; David H Rowitch
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

8.  Moderate postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin.

Authors:  Jen-Ruey Tang; Gregory J Seedorf; Vincent Muehlethaler; Deandra L Walker; Neil E Markham; Vivek Balasubramaniam; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-13       Impact factor: 5.464

9.  Connective tissue growth factor expression pattern in lung development.

Authors:  Carmen Mesas Burgos; Magnus Nord; Abraham Roos; Lukas Didon; Ann-Christine Eklöf; Björn Frenckner
Journal:  Exp Lung Res       Date:  2010-10       Impact factor: 2.459

10.  Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort.

Authors:  Jennifer Zeitlin; Mayass El Ayoubi; Pierre-Henri Jarreau; Elizabeth S Draper; Béatrice Blondel; Wolfgang Künzel; Marina Cuttini; Monique Kaminski; Ludwig Gortner; Patrick Van Reempts; Louis Kollée; Emile Papiernik
Journal:  J Pediatr       Date:  2010-06-17       Impact factor: 4.406

View more
  24 in total

Review 1.  Sonic hedgehog signaling in the lung. From development to disease.

Authors:  Matthias C Kugler; Alexandra L Joyner; Cynthia A Loomis; John S Munger
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

2.  Epithelial-mesenchymal co-culture model for studying alveolar morphogenesis.

Authors:  Rachel M Greer; J Davin Miller; Victor O Okoh; Brian A Halloran; Lawrence S Prince
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

3.  Cumulative effects of neonatal hyperoxia on murine alveolar structure and function.

Authors:  Angela M Cox; Yong Gao; Anne-Karina T Perl; Robert S Tepper; Shawn K Ahlfeld
Journal:  Pediatr Pulmonol       Date:  2017-02-10

4.  The innate immune response in fetal lung mesenchymal cells targets VEGFR2 expression and activity.

Authors:  Rachel M Medal; Amanda M Im; Yasutoshi Yamamoto; Omar Lakhdari; Timothy S Blackwell; Hal M Hoffman; Debashis Sahoo; Lawrence S Prince
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-23       Impact factor: 5.464

5.  Fra-2 negatively regulates postnatal alveolar septation by modulating myofibroblast function.

Authors:  Kazuyuki Tsujino; John T Li; Tatsuya Tsukui; Xin Ren; Latifa Bakiri; Erwin Wagner; Dean Sheppard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-17       Impact factor: 5.464

6.  Initial Suppression of Transforming Growth Factor-β Signaling and Loss of TGFBI Causes Early Alveolar Structural Defects Resulting in Bronchopulmonary Dysplasia.

Authors:  Shawn K Ahlfeld; Jian Wang; Yong Gao; Paige Snider; Simon J Conway
Journal:  Am J Pathol       Date:  2016-02-13       Impact factor: 4.307

Review 7.  Glucocorticoid regulation of lung development: lessons learned from conditional GR knockout mice.

Authors:  A Daniel Bird; Annie R A McDougall; Bennet Seow; Stuart B Hooper; Timothy J Cole
Journal:  Mol Endocrinol       Date:  2014-12-23

Review 8.  Update on Molecular Biology of Lung Development--Transcriptomics.

Authors:  Thomas J Mariani
Journal:  Clin Perinatol       Date:  2015-12       Impact factor: 3.430

9.  Mechanisms of bronchopulmonary dysplasia.

Authors:  Antonia P Popova
Journal:  J Cell Commun Signal       Date:  2013-01-20       Impact factor: 5.782

10.  Maternal/neonatal vitamin D deficiency: a risk factor for bronchopulmonary dysplasia in preterms?

Authors:  M Çetinkaya; F Çekmez; T Erener-Ercan; G Buyukkale; A Demirhan; G Aydemir; F N Aydin
Journal:  J Perinatol       Date:  2015-07-30       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.